Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 17, 2021

University Hospitals selects GenomOncology platform for trials

University Hospitals Seidman Cancer Center in the US has selected GenomOncology's Precision Decision and GO Connect solutions to streamline the matching of patients to the increasing number of clinical trials and therapies.

University Hospitals Seidman Cancer Center in the US has selected GenomOncology’s Precision Decision and GO Connect solutions to streamline the matching of patients to the increasing number of clinical trials and therapies.

The platform will help University Hospitals to help scale its precision oncology programme and streamlines a complicated process to assist patients and doctors.

University Hospitals selected the new platform as it needed access to all curated biomarker-based and institutional non-biomarker clinical trials.

GenomOncology’s platform also provides the capability to identify cohorts of patients within the institution eligible for clinical trials and novel therapies.

Additionally, it allows University Hospitals to conduct feasibility analysis to launch new clinical trials across all of its locations wholly-owned by Seidman Cancer Center.

University Hospitals Seidman Cancer Center president and scientific director Dr Theodoros Teknos said: “Due to the speed and complexity of genetic and biomarker discoveries, it is virtually impossible for any oncologist to remain current on all the clinical trials and newly approved cancer therapies.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

“Through this partnership with GenomOncology, we have leveraged the power of computing to process incredible amounts of data and identify the optimal care for every patient.”

University Hospitals will use GenomOncology’s Precision Decision and GO Connect solutions to efficiently match patients to therapies, as well as relevant, open clinical trials.

The solution will also be used to ingest data from the institutions’ clinical data warehouse and clinical trial matching system and transform it into usable information available within GenomOncology’s Precision Decision product.

University Hospitals will also be able to identify and interact with all therapies and curated clinical trials in a single dashboard, through which users can search for eligible patients at their institution.

The University Hospitals team can also examine their internal database of clinical and molecular profiles of patients to determine the feasibility of opening new clinical trials.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU